3,5-di-(4-morpholinyl)toluene | 28495-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3,5-di-(4-morpholinyl)toluene
• 英文别名: 3,5-Dimorpholinotoluol；1,3-Dimorpholino-5-methylbenzol；4,4'-(5-methyl-m-phenylene)-bis-morpholine；4-(3-Methyl-5-morpholin-4-ylphenyl)morpholine
• CAS: 28495-04-7
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: NAQQJOOXCXQMHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  24.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  吗啉 、 3,5-二溴甲苯 在 bromopalladium(1+);N'-(naphthalen-1-ylmethylideneamino)carbamimidothioate;triphenylphosphane 、 potassium carbonate 作用下， 以 仲丁醇 为溶剂， 反应 24.0h， 以73.2%的产率得到3,5-di-(4-morpholinyl)toluene
  参考文献：
  名称：

  Synthesis and structural characterization of palladium(II) thiosemicarbazone complex: application to the Buchwald–Hartwig amination reaction

  摘要：

  A simple route to synthesize mononuclear palladium(II) thiosemicarbazone complex has been described. Elemental analysis, spectral methods and single crystal X-ray diffraction analysis were used to confirm the composition of the complex. The new complex acts as an active homogeneous catalyst for the Buchwald-Hartwig amination reaction of a wide range of aryl and heteroaryl halides (bromides and chlorides), including activating, neutral and deactivating substrates, with various secondary amines under optimized conditions. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.12.070

文献信息

• PYRIMIDINE DERIVATIVES
  申请人：Kettle Jason Grant

  公开号：US20110046108A1

  公开（公告）日：2011-02-24

  The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
• A stable (amino)(phosphino)carbene as bidentate ligand for palladium and nickel complexes: Synthesis, structure, and catalytic activity
  作者：Emmanuelle Teuma、Céline Lyon-Saunier、Heinz Gornitzka、Gérard Mignani、Antoine Baceiredo、Guy Bertrand

  DOI：10.1016/j.jorganchem.2005.06.036

  日期：2005.12

  Two original complexes featuring an (amino)(phosphino)carbene η2-bonded to the metal have been obtained in 60% and 80% yields, by addition of the corresponding stable carbene to PdCl2(cod) and NiCl2(PPh3)2, respectively. Both complexes have been fully characterized including X-ray diffraction studies. The catalytic activity of the palladium complex has been evaluated for aryl amination reactions.

  通过将相应的稳定卡宾添加到 PdCl 2 (cod) 和 NiCl 2 (PPh 3 ) 中，以 60% 和 80% 的收率获得了两种以 (氨基)(膦基) 卡宾 η 2键合到金属上的原始配合物2、分别。两种配合物都已得到充分表征，包括 X 射线衍射研究。钯配合物的催化活性已针对芳基胺化反应进行了评估。
• NOVEL PYRIMIDINE DERIVATIVES 698
  申请人：Ashton Susan Elizabeth

  公开号：US20080242663A1

  公开（公告）日：2008-10-02

  The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R 1 , n, R 2 , R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.

  本发明涉及公式I的化合物或其药学上可接受的盐，其中R1、n、R2、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、包含它们的药物组合物以及它们在制造用于作为抗增殖剂用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病的药物的用途。
• USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS
  申请人：Dana Farber Cancer Institute, Inc.

  公开号：EP3536323A1

  公开（公告）日：2019-09-11

  The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).

  本公开提供了使用盐诱导激酶(SIK)抑制剂，如式(I)的大环SIK抑制剂、式(II)的咪唑基SIK抑制剂和式(III-A)的脲和氨基甲酸酯SIK抑制剂(例如，式(III)的脲和氨基甲酸酯SIK抑制剂)治疗和/或预防炎症性肠病(IBD)和移植物抗宿主病(GVHD)的方法。
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2007085833A2

  公开（公告）日：2007-08-02

  [EN] The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R¹, ring A, n, R³, and R⁴ are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
  [FR] La présente invention concerne des composés de benzamide de Formule (I) ou un sel dérivé pharmaceutiquement acceptable, où R¹, le cycle A, n, R³, et R⁴ sont tels qu'énoncés dans la description. La présente invention a aussi trait à des processus de préparation de tels composés, à des compositions pharmaceutiques les contenant et à leur utilisation dans la fabrication d'un médicament à utiliser comme agent antiproliférateur pour la prévention ou le traitement de tumeurs ou d'autres conditions prolifératrices qui sont sensibles à l'inhibition des kinases EphB4, et/ou EphA2 et/ou Src.